{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:18:02Z","timestamp":1793513882989,"version":"4.5.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:00:00Z","timestamp":1684540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Carcinoid heart disease (CaHD) is an important complication among patients with metastatic neuroendocrine tumors and carcinoid syndrome (CS). CS patients (25%-65%) eventually develop CaHD; these patients face a significantly increased risk of morbidity and mortality. Guidance papers (eg, clinical practice guidelines, consensus guidelines, and expert statements) have been established by major organizations across the disciplines of cardiology and oncology; however, these recommendations are not routinely implemented. The aim of this article is to encourage the integration of current recommendations from national societies into clinical practice. Early screening upon recognition of CS and prior to the development of CaHD symptoms is paramount, as no existing therapies are approved to reverse the fibrotic damage to the heart once it occurs. Valvular replacement is the only definitive treatment for CaHD once it has developed. When patients are noted to have urinary 5-hydroxyindoleacetic acid (5-HIAA) levels \u2265300 \u00b5mol\/24 h and\/or serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels &amp;gt;260 pg\/mL, echocardiography is recommended. Systemic approaches to control tumor growth and hormonal secretion include somatostatin analogs (SSAs), followed by options including peptide receptor radiotherapy (PRRT), everolimus and liver embolization. Telotristat is the primary choice for control of diarrhea refractory to SSA. Diuretics are the mainstay of heart failure symptom management for patients who develop CaHD. Considerations for future research are discussed, including the ongoing TELEHEART (TELotristat Ethyl in a HEART biomarker study) trial involving telotristat and not yet activated CHARRT (Carcinoid Heart disease And peptide Receptor Radiotargetted Therapy) study involving PRRT with lutetium 177 (177Lu) dotatate.<\/jats:p>","DOI":"10.1093\/oncolo\/oyad126","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:42:04Z","timestamp":1684615324000},"page":"575-583","source":"Crossref","is-referenced-by-count":15,"title":["Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-1039","authenticated-orcid":false,"given":"Satya","family":"Das","sequence":"first","affiliation":[{"name":"Late Development Oncology, GI, AstraZeneca , Gaithersburg, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon S","family":"Stockton","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saamir A","family":"Hassan","sequence":"additional","affiliation":[{"name":"Ascension Texas Cardiovascular , Cedar Park, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,20]]},"reference":[{"key":"2023070520014608400_CIT0001","first-page":"387","article-title":"The carcinoid endocardial plaque; an ultrastructural study","volume-title":"Hum Pathol","author":"Ferrans","year":"1976"},{"issue":"6","key":"2023070520014608400_CIT0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pcad.2006.12.002","article-title":"Carcinoid heart disease","volume":"49","author":"Bernheim","year":"2007","journal-title":"Prog Cardiovasc :Dis"},{"key":"2023070520014608400_CIT0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020475","article-title":"Progression of carcinoid heart disease in the modern management era","volume-title":"J Am Heart Assoc","author":"Baron","year":"2021"},{"key":"2023070520014608400_CIT0004","first-page":"1221","article-title":"Risk factors for the development and progression of carcinoid heart disease","volume-title":"Am J Cardiol","author":"Bhattacharyya","year":"2011"},{"issue":"10","key":"2023070520014608400_CIT0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2023070520014608400_CIT0006","first-page":"1288","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume-title":"J Am Coll Cardiol","author":"Davar","year":"2017"},{"issue":"4","key":"2023070520014608400_CIT0007","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol."},{"key":"2023070520014608400_CIT0008","first-page":"665","article-title":"The prevalence, operations, and outcomes of carcinoid heart disease","volume-title":"Am J Surg","author":"Macfie","year":"2022"},{"issue":"24","key":"2023070520014608400_CIT0009","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1002\/cncr.31079","article-title":"Neuroendocrine tumors and fibrosis: an unsolved mystery?","volume":"123","author":"Laskaratos","year":"2017","journal-title":"Cancer"},{"issue":"6187","key":"2023070520014608400_CIT0010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/335254a0","article-title":"Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein","volume":"335","author":"Seuwen","year":"1988","journal-title":"Nature"},{"key":"2023070520014608400_CIT0011","first-page":"46","article-title":"Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture","volume-title":"Am J Physiol","author":"Lee","year":"1994"},{"issue":"12","key":"2023070520014608400_CIT0012","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"2023070520014608400_CIT0013","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"issue":"1","key":"2023070520014608400_CIT0014","first-page":"71","article-title":"Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease","volume":"142","author":"Waltenberger","year":"1993","journal-title":"Am J Pathol"},{"issue":"4","key":"2023070520014608400_CIT0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000381930","article-title":"Carcinoid heart disease: from pathophysiology to treatment\u2014\u201cSomething in the way it moves.\u201d","volume":"101","author":"Grozinsky-Glasberg","year":"2015","journal-title":"Neuroendocrinology"},{"key":"2023070520014608400_CIT0016","first-page":"1328","article-title":"Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients","volume-title":"J Am Coll Cardiol","author":"Pandya","year":"2002"},{"key":"2023070520014608400_CIT0017","first-page":"1179","article-title":"Carcinoid heart disease: how to diagnose and treat in 2020?","volume-title":"Clin Med Insights Cardiol.","author":"Bober","year":"2020"},{"issue":"4","key":"2023070520014608400_CIT0018","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"issue":"21","key":"2023070520014608400_CIT0019","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1161\/CIRCULATIONAHA.105.553750","article-title":"Prognosis of carcinoid heart disease: analysis of 200 cases over two decades","volume":"112","author":"M\u00f8ller","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"2023070520014608400_CIT0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"2023070520014608400_CIT0021","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease","volume-title":"J Neuroendocrinol","author":"Grozinsky-Glasberg","year":"2022"},{"key":"2023070520014608400_CIT0022","volume-title":"\u00a9 National Comprehensive Cancer Network, Inc","author":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Neuroendocrine and adrenal tumors V.1.2022."},{"key":"2023070520014608400_CIT0023","first-page":"547","article-title":"Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients","volume-title":"Neuroendocrinology","author":"Fijalkowski","year":"2022"},{"key":"2023070520014608400_CIT0024","first-page":"65","article-title":"Carcinoid heart disease: pathophysiology, pathology, clinical manifestations, and management","volume-title":"Cardiology","author":"Jin","year":"2021"},{"issue":"3","key":"2023070520014608400_CIT0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9343(85)90313-4","article-title":"The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease","volume":"79","author":"Ross","year":"1985","journal-title":"Am J Med"},{"issue":"9","key":"2023070520014608400_CIT0026","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2014.468","article-title":"Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality","volume":"111","author":"Dobson","year":"2014","journal-title":"Br J Cancer"},{"key":"2023070520014608400_CIT0027","first-page":"1084","article-title":"Small intestinal neuroendocrine tumors: prognostic factors and survival","volume-title":"Scand J Gastroenterol","author":"Bergestuen","year":"2009"},{"key":"2023070520014608400_CIT0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2018.09.025","article-title":"Improving outcome of valve replacement for carcinoid heart disease","volume-title":"J Thorac Cardiovasc Surg.","author":"Nguyen","year":"2019"},{"issue":"2","key":"2023070520014608400_CIT0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.surg.2021.02.054","article-title":"Outcomes of surgical treatment for carcinoid heart disease: a systematic review and meta-analysis","volume":"170","author":"O\u2019Malley","year":"2021","journal-title":"Surgery"},{"key":"2023070520014608400_CIT0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2019.06.013","article-title":"Burden of carcinoid heart disease in patients with carcinoid syndrome initiating somatostatin analogues","volume-title":"Clin Ther.","author":"Joish","year":"2019"},{"key":"2023070520014608400_CIT0031","first-page":"1509","article-title":"Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study","volume-title":"Scand J Gastroenterol","author":"Les\u00e9n","year":"2018"},{"issue":"6","key":"2023070520014608400_CIT0032","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0016-5085(78)90084-7","article-title":"Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors","volume":"75","author":"Feldman","year":"1978","journal-title":"Gastroenterology"},{"issue":"7","key":"2023070520014608400_CIT0033","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"2023070520014608400_CIT0034","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0735-1097(98)00354-4","article-title":"Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease","volume":"32","author":"Denney","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2023070520014608400_CIT0035","first-page":"865","article-title":"Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome","volume-title":"Br J Surg","author":"Westberg","year":"2001"},{"key":"2023070520014608400_CIT0036","first-page":"1","article-title":"Carcinoid heart disease: prognostic value of 5-hydroxyindoleacetic acid levels and impact on survival: a systematic literature review","volume-title":"Neuroendocrinology","author":"Buchanan-Hughes","year":"2021"},{"key":"2023070520014608400_CIT0037","first-page":"1005","article-title":"Factors associated with progression of carcinoid heart disease","volume-title":"N Engl J Med","author":"M\u00f8ller","year":"2003"},{"key":"2023070520014608400_CIT0038","first-page":"1086","article-title":"Validation of HPLC-amperometric detection to measure serotonin in plasma, platelets, whole blood, and urine","volume-title":"Clin Chem","author":"Pussard","year":"1996"},{"key":"2023070520014608400_CIT0039","first-page":"554","article-title":"Serum and plasma \u00ad5-hydroxyindoleacetic acid as an alternative to 24-h urine \u00ad5-hydroxyindoleacetic acid measurement","volume-title":"Ann Clin Biochem.","author":"Adaway","year":"2016"},{"key":"2023070520014608400_CIT0040","first-page":"76","article-title":"The role of serum 5-HIAA as a predictor of progression and an alternative to 24-h urine 5-HIAA in well-differentiated neuroendocrine neoplasms","volume-title":"Biology (Basel)","author":"Wedin","year":"2021"},{"issue":"12","key":"2023070520014608400_CIT0041","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/fon-2018-0960","article-title":"Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis","volume":"15","author":"Joish","year":"2019","journal-title":"Future Oncol"},{"issue":"11","key":"2023070520014608400_CIT0042","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/sj.bjc.6601816","article-title":"Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease","volume":"90","author":"Zuetenhorst","year":"2004","journal-title":"Br J Cancer"},{"key":"2023070520014608400_CIT0043","first-page":"938","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume-title":"Am J Cardiol","author":"Bhattacharyya","year":"2008"},{"key":"2023070520014608400_CIT0044","first-page":"2361","article-title":"Elevated serotonin and NT-proBNP levels predict and detect carcinoid heart disease in a large validation study","volume-title":"Cancers (Basel)","author":"Levy","year":"2022"},{"key":"2023070520014608400_CIT0045","first-page":"4293","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor","volume-title":"J Clin Oncol","author":"Korse","year":"2009"},{"key":"2023070520014608400_CIT0046","first-page":"171","article-title":"Levels of NT-proBNP and troponin T in cancer patients\u2014mini-review","volume-title":"Klin Onkol","author":"Chovanec","year":"2020"},{"key":"2023070520014608400_CIT0047","first-page":"534","article-title":"Elevated plasma pancreastatin, but not chromogranin A, predicts survival in neuroendocrine tumors of the duodenum","volume-title":"J Am Coll Surg","author":"Woltering","year":"2016"},{"issue":"3","key":"2023070520014608400_CIT0048","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000318014","article-title":"Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis","volume":"92","author":"Bergestuen","year":"2010","journal-title":"Neuroendocrinology"},{"key":"2023070520014608400_CIT0049","first-page":"304","article-title":"Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS Center of Excellence experience","volume-title":"Neuroendocrinology","author":"Malczewska","year":"2021"},{"key":"2023070520014608400_CIT0050","first-page":"503","article-title":"Foundational statistical principles in medical research: sensitivity, specificity, positive predictive value, and negative predictive value","volume-title":"Medicina (Kaunas)","author":"Monaghan","year":"2021"},{"key":"2023070520014608400_CIT0051","first-page":"103","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI","volume-title":"Circ Cardiovasc Imaging","author":"Bhattacharyya","year":"2010"},{"issue":"3","key":"2023070520014608400_CIT0052","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2007.08.045","article-title":"Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century","volume":"101","author":"Bhattacharyya","year":"2007","journal-title":"Am J Cardiol"},{"key":"2023070520014608400_CIT0053","first-page":"R145","article-title":"Management of carcinoid syndrome: a systematic review and meta-analysis","volume-title":"Endocr Relat Cancer","author":"Hofland","year":"2019"},{"key":"2023070520014608400_CIT0054","first-page":"14","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume-title":"J Clin Oncol","author":"Kulke","year":"2017"},{"issue":"3","key":"2023070520014608400_CIT0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2023070520014608400_CIT0056","first-page":"2144170","article-title":"External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy","volume-title":"JAMA Netw Open.","author":"Das","year":"2022"},{"key":"2023070520014608400_CIT0057","doi-asserted-by":"crossref","article-title":"Screening for carcinoid heart disease: future perspectives.","author":"Mouser","DOI":"10.1016\/j.ijcrp.2024.200293"},{"key":"2023070520014608400_CIT0058","doi-asserted-by":"crossref","first-page":"945672","DOI":"10.3389\/fcvm.2022.945672","article-title":"Telotristat ethyl reverses myxomatous changes in mice mitral valves","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023070520014608400_CIT0059","first-page":"51","article-title":"Cardiovascular remodeling and the peripheral serotonergic system","volume-title":"Arch Cardiovasc Dis","author":"Ayme-Dietrich","year":"2017"},{"key":"2023070520014608400_CIT0060","first-page":"48","article-title":"Carcinoid heart disease: a review","volume-title":"Curr Oncol Rep","author":"Laskaratos","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/575\/50825976\/oyad126.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/7\/575\/50825976\/oyad126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T20:28:06Z","timestamp":1729456086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/7\/575\/7174955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,20]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,5,20]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad126","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,5,20]]}}}